An Open Label Non-randomized Phase II Study Exploring "Chemo-free " Treatment Association With Idelalisib + Obinutuzumab in Patient With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Trial Profile

An Open Label Non-randomized Phase II Study Exploring "Chemo-free " Treatment Association With Idelalisib + Obinutuzumab in Patient With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Idelalisib (Primary) ; Obinutuzumab (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Acronyms RemodelWM3
  • Most Recent Events

    • 07 Mar 2017 Planned End Date changed from 1 Dec 2018 to 1 Mar 2025.
    • 07 Mar 2017 Planned primary completion date changed from 2 Jan 2017 to 1 Mar 2019.
    • 03 Feb 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top